Sandoz Inc. C/O Exel, Inc. Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Sandoz Inc. C/O Exel, Inc. Pharmaceutical Import Records from India — 6 Products, $23.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sandoz Inc. C/O Exel, Inc. — Pharmaceutical Importer Profile (2026) | 6 Products, $23.8M Trade | TransData Nexus

Sandoz Inc. C/O Exel, Inc.

Pharmaceutical Importer · United States · Immunosuppressants Focus · $23.8M Total Trade · DGFT Verified

Sandoz Inc. C/O Exel, Inc. is a pharmaceutical importer based in United States with a total trade value of $23.8M across 6 products in 5 therapeutic categories. Based on 525 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sandoz Inc. C/O Exel, Inc. sources from 1 verified Indian supplier, with Sandoz Private Limited accounting for 100.0% of imports.

Sandoz Inc. C/O Exel, Inc. — Import Portfolio & Supplier Network

Sandoz Inc. C/O Exel, Inc. import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sandoz Inc. C/O Exel, Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$13.7M	307	100.0%

Sandoz Inc. C/O Exel, Inc. sources from 1 verified Indian supplier across 110 distinct formulations. The sourcing is highly concentrated — Sandoz Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Sandoz Inc. C/O Exel, Inc. Import?

Formulation	Value	Ships
Tacrolimus 1MG 100hgc bo us material no.-	$2.0M	40
Hydroxyzine 25MG 500hgc bo v1 us material no	$651.8K	15
Tacrolimus 1MG 100hgc bo us material no.	$650.0K	13
Material no. - 44073589 hydroxyzine 50MG	$600.0K	12
Hydroxyzine 25MG 100hgc bo v1 us material no. -	$600.0K	12
Hydroxyzine 50MG 100hgc bo v1 us	$550.0K	11
Tacrolimus 1MG 100hgc bo us material no	$500.0K	10
Hydroxyzine 50MG 500hgc bo v1 us	$500.0K	10
Tacrolimus 0.5MG 100hgc bo us material no. -	$460.3K	10
Mycophenolate mof 500MG 100fct bo us	$450.0K	9
Tacrolimus 0.5MG 100hgc bo us material	$427.1K	9
Hydroxyzine 25MG 500hgc bo v1 us	$400.0K	8
Hydroxyzine 50MG 500hgc bo v1 us material no. -	$393.9K	8
Mycophenolate mof 250MG 100hgc bo us material no. -	$349.5K	7
Hydroxyzine 25MG 100hgc bo v1 us	$300.0K	6

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tacrolimus	Immunosuppressants	$14.5M	290	4.7%	2
2	Mycophenolate	Immunosuppressants	$5.5M	110	1.1%	6
3	Alprazolam	CNS & Psychiatric	$2.0M	58	11.9%	3
4	Carvedilol	Cardiovascular	$1.1M	51	1.1%	14
5	Nitrofurantoin	Advanced Antibiotics	$500.0K	10	0.7%	6
6	Voriconazole	Advanced Antifungals	$300.0K	6	1.0%	13

Sandoz Inc. C/O Exel, Inc. imports 6 pharmaceutical products across 5 categories into United States totaling $23.8M.

Sandoz Inc. C/O Exel, Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sandoz Inc., operating through Exel, Inc., is a prominent pharmaceutical importer and distributor based in the United States. Headquartered at 350 Salem Church Road, Mechanicsburg, Pennsylvania, the company specializes in the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products are sourced primarily from India, with a total import value of $23.8 million USD over 525 shipments from 2022 to 2026. The imported products span six distinct therapeutic categories, underscoring Sandoz Inc.'s diverse portfolio.

As a subsidiary of Sandoz Group AG, a global leader in generic pharmaceuticals and biosimilars, Sandoz Inc. plays a crucial role in the U.S. pharmaceutical supply chain. The company serves as a key importer, ensuring the availability of a wide range of generic medications to meet the demands of the U.S. market. By leveraging its extensive distribution network, Sandoz Inc. contributes significantly to the accessibility and affordability of essential medicines across the United States.

2Distribution Network

Sandoz Inc., through Exel, Inc., maintains a robust distribution network across the United States, with a primary warehouse located at 350 Salem Church Road, Mechanicsburg, Pennsylvania. This strategic location facilitates efficient logistics and timely delivery of pharmaceutical products nationwide. The company's logistics capabilities are enhanced by its partnership with Exel, Inc., a global leader in supply chain management, ensuring streamlined operations and adherence to regulatory standards. While specific details about additional warehouse locations and international distribution centers are not publicly disclosed, Sandoz Inc.'s extensive import activities from India and other countries suggest a well-established global supply chain. This network enables the company to effectively serve the diverse needs of the U.S. pharmaceutical market.

3Industry Role

Sandoz Inc., operating through Exel, Inc., functions as a pharmaceutical importer and distributor within the United States. The company is not classified as a primary wholesaler, parallel importer, hospital supplier, or logistics intermediary. Instead, it focuses on the importation and distribution of finished pharmaceutical formulations sourced from international suppliers, particularly from India. By importing a diverse range of generic medications, Sandoz Inc. plays a pivotal role in enhancing the availability and affordability of essential drugs in the U.S. market. Its operations contribute to the overall efficiency and competitiveness of the pharmaceutical supply chain, ensuring that healthcare providers and patients have access to a broad spectrum of therapeutic options.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sandoz Inc. C/O Exel, Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sandoz Inc.'s sourcing strategy exhibits a high degree of concentration, with a total import value of $23.8 million USD over 525 shipments from India between 2022 and 2026. The company's portfolio comprises six products across five therapeutic categories, with the top five products accounting for 98.7% of the total import value. This concentration indicates a strategic focus on specific high-demand medications, which can lead to cost efficiencies and streamlined supply chain management.

However, the reliance on a single supplier, Sandoz Private Limited, for all imports from India introduces potential risks. Any disruptions in Sandoz Private Limited's operations—such as production delays, quality control issues, or regulatory challenges—could significantly impact Sandoz Inc.'s ability to meet market demand. The absence of alternative suppliers in the Indian market further exacerbates this risk. To mitigate such vulnerabilities, Sandoz Inc. may consider diversifying its supplier base and establishing contingency plans to ensure a resilient supply chain.

2Supply Chain Resilience

Sandoz Inc.'s supply chain resilience is currently limited due to its exclusive reliance on Sandoz Private Limited for imports from India. This single-source dependency means that any disruptions affecting Sandoz Private Limited—such as production delays, quality control issues, or regulatory challenges—could significantly impact Sandoz Inc.'s ability to meet market demand. The absence of backup suppliers in the Indian market further exacerbates this risk.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces several key pieces of legislation governing pharmaceutical imports, including the Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Enforcement Administration (DEA) regulations. These laws establish the requirements for drug approval, labeling, manufacturing practices, and importation procedures.

For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process. This pathway allows for the approval of generic drugs that are bioequivalent to their brand-name counterparts, facilitating market entry while ensuring safety and efficacy. The FDA's rigorous evaluation process includes assessments of the drug's chemistry, manufacturing controls, labeling, and bioequivalence studies. Compliance with these regulatory requirements is essential for Indian pharmaceutical companies aiming to supply products to the U.S. market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All imported drugs must be approved by the FDA, which involves submitting an ANDA for generics or a New Drug Application (NDA) for new drugs. Additionally, the FDA requires that foreign manufacturers comply with Good Manufacturing Practice (GMP) standards, which are enforced through inspections and certifications.

Sandoz Inc. C/O Exel, Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sandoz Inc.'s product strategy focuses on importing a select range of high-demand generic medications, particularly in the therapeutic areas of immunosuppressants, central nervous system (CNS) and psychiatric disorders, and cardiovascular diseases. The company's top five imported products—Tacrolimus, Mycophenolate, Alprazolam, Carvedilol, and Nitrofurantoin—account for 98.7% of the total import value. This concentrated approach allows Sandoz Inc. to leverage economies of scale and maintain a streamlined supply chain.

The market demand

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Sandoz Inc. C/O Exel, Inc.

What products does Sandoz Inc. C/O Exel, Inc. import from India?

Sandoz Inc. C/O Exel, Inc. imports 6 pharmaceutical products across 5 categories. Top imports: Tacrolimus ($14.5M), Mycophenolate ($5.5M), Alprazolam ($2.0M), Carvedilol ($1.1M), Nitrofurantoin ($500.0K).

Who supplies pharmaceuticals to Sandoz Inc. C/O Exel, Inc. from India?

Sandoz Inc. C/O Exel, Inc. sources from 1 verified Indian suppliers. The primary supplier is Sandoz Private Limited (100.0% of imports, $13.7M).

What is Sandoz Inc. C/O Exel, Inc.'s total pharmaceutical import value?

Sandoz Inc. C/O Exel, Inc.'s total pharmaceutical import value from India is $23.8M, based on 525 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sandoz Inc. C/O Exel, Inc. focus on?

Sandoz Inc. C/O Exel, Inc. imports across 5 categories. The largest: Immunosuppressants (83.9%), CNS & Psychiatric (8.3%), Cardiovascular (4.4%).

Get Full Sandoz Inc. C/O Exel, Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.